A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF DURVALUMAB (MEDI4736) +/- TREMELIMUMAB, VERSUS STANDARD OF CARE (SOC), IN PLATINUM-RESISTANT RECURRENT OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): EAGLE
Chemotherapy / Radiation / Adjuvant Treatment
Robert L Ferris1, Mikhail Dvorkin PhD2, Jerome Fayette3, Paul Clement4, Caroline Even5, Eva Remenar6, Robert Haddad7, Makoto Tahara8, Trishna Goswami9, April Franks9, Ugochi Emeribe9, Giovanni Melillo9, Lisa Licitra10
1Department of Otolaryngology and Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA, 2Budgetary Healthcare Institution of Omsk Region "Clinical Oncologic Dispensary", 3Centre Léon Bérard, Lyon, France, 4Universitair Ziekenhuis Leuven, Leuven, Belgium, 5Head and Neck Oncology, Institut Gustave-Roussy, Villejuif, France, 6Országos Onkológiai Intézet, Budapest, Hungary, 7Dana Farber Cancer Institute, Boston, USA, 8Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 9Immuno-Oncology GMD, AstraZeneca, Gaithersburg, USA, 10Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy